Showing results (1-10 of 32) with videos related to
Sort By:
Pageof 4
Current Hematologic Malignancy Reports|November 6, 2023
Measurable Residual Disease Monitoring in LymphomaBrian Cuzzo, Andrew Lipsky, Hua-Jay J CherngHematology/Oncology Clinics of North America|June 27, 2021
First-Line Therapy for Chronic Lymphocytic Leukemia: Bruton Tyrosine Kinase or BCL2 or Both?Hua-Jay J Cherng, Nitin JainCurrent Treatment Options in Oncology|April 24, 2024
Circulating Tumor DNA in Diffuse Large B-Cell Lymphoma: from Bench to Bedside?Hua-Jay J Cherng, Alex HerreraLeukemia & Lymphoma|January 6, 2021
Why R-CHOP + X is not enough: lessons learned and next steps in the mission to improve frontline therapy for diffuse large B-cell lymphomaHua-Jay J Cherng, Jason WestinClinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 21, 2022
Broadening the MIND: Tafasitamab and Lenalidomide versus Synthetic ControlsHua-Jay J Cherng, Jason R WestinCancers|April 14, 2025
Measurable Residual Disease Testing During Treatment with Bispecific Antibodies for LymphomaGaston Jean-Louis, Hua-Jay J CherngLeukemia & Lymphoma|June 7, 2026
Treatment intensity, illness burden, and disparities in newly diagnosed diffuse large B-cell lymphoma treated at an urban academic centerHua-Jay J Cherng, David DeStephano, Patrick Gould, et al.The American Journal of the Medical Sciences|July 24, 2019
Comprehensive Analysis of Temperature in Hospitalized PatientsIvayla I Geneva, Brian Cuzzo, Tasaduq Fazili, et al.Open Forum Infectious Diseases|April 13, 2019
Normal Body Temperature: A Systematic ReviewIvayla I Geneva, Brian Cuzzo, Tasaduq Fazili, et al.Hematology. American Society of Hematology. Education Program|December 4, 2020
Managing toxicities of Bruton tyrosine kinase inhibitorsAndrew Lipsky, Nicole LamannaPageof 4